<DOC>
	<DOCNO>NCT03084952</DOCNO>
	<brief_summary>It randomize phase II clinical study , unicentre aim evaluate tolerability , safety efficacy 18-Methoxyoronaridine candidate tegumentary leishmaniasis treatment .</brief_summary>
	<brief_title>Phase 2 Trial Evaluate 18-Methoxycoronaridine Efficacy , Safety Tolerability Cutaneous Leishmaniasis Patients</brief_title>
	<detailed_description />
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Cutaneous</mesh_term>
	<mesh_term>Drug-Related Side Effects Adverse Reactions</mesh_term>
	<mesh_term>Meglumine antimoniate</mesh_term>
	<mesh_term>Ibogaine</mesh_term>
	<criteria>Age 18 59 year age ; Clinical diagnosis leishmaniasis least one ulcerated lesion evolution time one month ; Parasitological confirmation ; Women childbearing potential pregnant breastfeeding , confirm examination bHCG ( GonadotrophicChorionic Hormone beta ) time screen ; Men woman use barrier contraceptive method course study ; History disease comorbidities , opinion investigator , either put individual risk influence result ability subject participate study ; History presence gastrointestinal , hepatic , cardiac , renal disease know condition may interfere absorption , distribution , metabolism excretion investigational product ; Any evidence underlie serious disease ( cardiac , renal , hepatic pulmonary ) ; Pregnancy patient 's unwillingness use barrier contraceptive method 3 month therapy ; History gastrointestinal ulcer disease , inflammatory bowel disease , symptoms indigestion ; Any clinically important abnormality biochemistry , hematology , urinalysis clinical outcome judge investigator ; Any positive screening result hepatitis B antigens , hepatitis C antibody , human immunodeficiency virus ( HIV ) ; Any clinically significant abnormality rate , drive rest ECG morphology may interfere interpretation QT interval variation ; History cancer ; History drug abuse , judge investigator History alcohol abuse excessive alcohol consumption , judge investigator ; History smoke History severe allergy / hypersensitivity , judge investigator ; History hypersensitivity drug similar chemical structure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>safety</keyword>
	<keyword>pharmacokynetics</keyword>
	<keyword>leishmaniasis treatment</keyword>
</DOC>